Lumida
/NVAX
⌘K
Novavax Inc

Novavax Inc

NVAX
$9.42USD+1.29%+0.12 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$9 – $10

52W RANGE

$6
$12

AI Summary

Stalk
StalkMedium

NVAX is consolidating in a neutral to cautious phase within its Stage 2 uptrend, trading between the 9- and 20-day EMAs after a pullback from early-September highs. The long-term trend remains up above the 50- and 200-day SMAs, but short-term momentum has cooled with RSI near 58 and moderate Options Score. Under a speculative strategy, execution favors deferred entries on pullback acceptance into the EMA support zone, avoiding premature buys until clear support is confirmed.

  • Sanofi partnership expands licensed reach toward a $100B-plus vaccine market
  • Q2 product sales up 76% YoY to $19M, driven by Matrix-M adjuvant
  • Q2 revenue plunged to $57M from $239M YoY, showing high fluctuation
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.1B$2.0B$983.7M$682.2M$1.1B
YoY %+141.0%+72.9%-50.4%-30.7%+64.7%
P / Sales9.3x0.4x0.5x1.8x1.0x
EV / Sales10.5x1.2x2.5x4.2x2.0x
Gross Profit, Adj.$1.1B$1.1B$639.9M$479.4M$1.1B
YoY %+141.0%-5.8%-40.7%-25.1%+119.1%
Margin %100.0%54.5%65.1%70.3%93.5%
EV / Gross Profit10.5x2.2x3.8x6.0x2.1x
EBITDA, Adj.$-1.7B$-615.7M$-525.3M$-200.4M$578.3M
YoY %-306.5%+63.2%+14.7%+61.8%+388.5%
Margin %-146.0%-31.1%-53.4%-29.4%51.5%
EV / EBITDA-7.2x-3.8x-4.7x-14.4x3.9x
EBIT$-1.7B$-644.7M$-566.5M$-248.9M$452.8M
YoY %-304.7%+61.8%+12.1%+56.1%+281.9%
Margin %-147.1%-32.5%-57.6%-36.5%40.3%
EV / EBIT-7.1x-3.6x-4.3x-11.6x4.9x
Net Income$-1.7B$-657.9M$-545.1M$-187.5M$440.3M
YoY %-316.9%+62.3%+17.2%+65.6%+334.8%
Net Margin-152.1%-33.2%-55.4%-27.5%39.2%
EPS (GAAP)-$23.44-$8.42-$5.41-$1.23$2.58
YoY %-222.4%+64.1%+35.7%+77.3%+309.8%